American Heart Journal
Volume 155, Issue 1 , Pages 56-61 , January 2008

Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: A potential approach to identify atherosclerotic disease progression

Received 10 May 2007 ,Accepted 22 August 2007.

References 

  1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69–e171
  2. Zipes DP, Camm AJ, Borggrefe M, et al. American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2006;114:e385–e484
  3. Burke AP, Kolodgie FD, Farb A, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation. 2001;103:934–940
  4. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 2003;41:15S–22S
  5. Corti R, Fuster V, Badimon JJ. Pathogenetic concepts of acute coronary syndromes. J Am Coll Cardiol. 2003;41:7S–14S
  6. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation. 2003;108:1772–1778
  7. Loftus IM, Naylor AR, Bell PR, et al. Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg. 2002;89:680–694
  8. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265:621–636
  9. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109(21 Suppl 1):II2–II10[Review]
  10. Kereiakes DJ. The emperor's clothes: in search of the vulnerable plaque. Circulation. 2003;107:2076–2077
  11. Kinlay S, Egido J. Inflammatory biomarkers in stable atherosclerosis. Am J Cardiol. 2006;98:S2–S8
  12. Fukuda D, Shimada K, Tanaka A, et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol. 2006;97:175–180
  13. Ferroni P, Basili S, Martini F, et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med. 2003;51:295–300
  14. Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods. 2000;243:243–255
  15. George J, Patal S, Wexler D, et al. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J. 2005;150:484–487
  16. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 1998;32:368–372
  17. Zeng B, Prasan A, Fung KC, Solanki V, et al. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J. 2005;35:331–335
  18. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail. 2004;10:328–333
  19. Barter PJ, Rye KA. The rationale for using apoA-I as a clinical marker of cardiovascular risk. J Intern Med. 2006;259:447–454
  20. Thompson GR. Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. Eur Heart J. 1998;19(Suppl H):H31–H36
  21. Kaprio J, Ferrell RE, Kottke BA, et al. Effects of polymorphisms in apolipoproteins E, A-IV, and H on quantitative traits related to risk for cardiovascular disease. Arterioscler Thromb. 1991;11:1330–1348

 The study was supported by Bayer HealthCare LLC, Morristown, NJ, and Sinai Hospital of Baltimore.

 Dr Paul A. Gurbel has received honoraria and grants from Haemoscope, Niles, IL; Astra Zeneca, London, United Kingdom; Schering Plough, Kenilworth, NJ; Medtronic, Minneapolis, MN; Lilly/Sankyo Sanofi, Paris, France; Boston-Scientific, Natick, MA; and Bayer, Pittsburgh, PA.

PII: S0002-8703(07)00707-7

doi: 10.1016/j.ahj.2007.08.021

American Heart Journal
Volume 155, Issue 1 , Pages 56-61 , January 2008

Article Tools